UY28486A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
UY28486A1
UY28486A1 UY28486A UY28486A UY28486A1 UY 28486 A1 UY28486 A1 UY 28486A1 UY 28486 A UY28486 A UY 28486A UY 28486 A UY28486 A UY 28486A UY 28486 A1 UY28486 A1 UY 28486A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
glycogen phosphorylase
activity
compounds
prodrug
Prior art date
Application number
UY28486A
Other languages
English (en)
Inventor
Bennett Stuart Norman Lile
Simpson Iain
Whittamore Paul Robert Owen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28486A1 publication Critical patent/UY28486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuesto de fórmula (1) o sal farmacéuticamente aceptable, profármaco donde R4, R5, R6, R7, A, n, R´, R2 y R3 son como se definen en la memoria y reivindicaciones, que posee actividad inhibidora de la glicógeno fosforilasa y concordantenente es de valor en el tratamiento de estados de enfermedad asociados con un incremento en la actividad de la glicógeno fosforilasa. Procesis para la fabricación de compuestos y composiciones farmacéuticas que los contienen.
UY28486A 2003-08-22 2004-08-20 Compuestos quimicos UY28486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0319759.7A GB0319759D0 (en) 2003-08-22 2003-08-22 Chemical compounds

Publications (1)

Publication Number Publication Date
UY28486A1 true UY28486A1 (es) 2005-03-31

Family

ID=28460130

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28486A UY28486A1 (es) 2003-08-22 2004-08-20 Compuestos quimicos

Country Status (8)

Country Link
US (1) US20060264494A1 (es)
EP (1) EP1656136A1 (es)
JP (1) JP2007503420A (es)
AR (1) AR045479A1 (es)
GB (1) GB0319759D0 (es)
TW (1) TW200524590A (es)
UY (1) UY28486A1 (es)
WO (1) WO2005018637A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
CZ2006427A3 (cs) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
AU2006335174B2 (en) 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP3296289A3 (en) 2007-05-31 2018-06-20 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2009158668A1 (en) * 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
US20060264494A1 (en) 2006-11-23
EP1656136A1 (en) 2006-05-17
JP2007503420A (ja) 2007-02-22
TW200524590A (en) 2005-08-01
AR045479A1 (es) 2005-10-26
WO2005018637A1 (en) 2005-03-03
GB0319759D0 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
UY28486A1 (es) Compuestos quimicos
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
ECSP055867A (es) Derivados de pirrolopirimidina
UY29616A1 (es) Compuestos químicos iii
UY29615A1 (es) Compuestos quimicos iv
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
UY28564A1 (es) Compuestos quimicos
PA8680701A1 (es) Derivados de oxindol
ATE433447T1 (de) Pyrimiidinverbindungen
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
UY29617A1 (es) Compuestos químicos vii
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE602004030689D1 (de) Verbindungen gegen entzündungen und immun-relevante verwendungen
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
NO20083207L (no) Inhibitorer av IAP
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
ATE473975T1 (de) Chemische verbindungen
DE602006001515D1 (de) Chemische verbindungen
TW200726748A (en) Chemical compounds II
UY28700A1 (es) Compuestos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150602